Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMWAEJ3)

Drug Name
GW803430 Drug Info
Synonyms
6-(4-Chlorophenyl)-3-(3-methoxy-4-(2-(pyrrolidin-1-yl)ethoxy)phenyl)thieno[3,2-d]pyrimidin-4(3H)-one; 515141-51-2; GW 803430; GW-3430; UNII-4R0136W1PR; GW-803430; Thieno[3,2-d]pyrimidin-4(3H)-one, 6-(4-chlorophenyl)-3-[3-methoxy-4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-; CHEMBL214957; GW-803,430; 4R0136W1PR; GW3430; 6-(4-Chlorophenyl)-3-(3-methoxy-4-(2-(pyrrolidin-1-yl)ethoxy)phenyl)thieno(3,2-d)pyrimidin-4(3H)-one; 6-(4-chlorophenyl)-3-(3-methoxy-4-(2-(pyrrolidin-1-yl)ethoxy)phenyl)thieno[3,2-d]pyrimidin-4(3H)-one; Thieno(3,2-d)pyrimidin-4(3H)-one,; GW-803,430
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
9826520
CAS Number
CAS 515141-51-2
TTD Drug ID
DMWAEJ3

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Patented Agent(s)
Approved Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Melanin-concentrating hormone receptor 1 (MCHR1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
BMS-830216 DMCW71N Obesity 5B81 Phase 1 [4]
AZD1979 DMQ1OX4 Obesity 5B81 Phase 1 [5]
PMID25522065-Compound-27 DMXN4KB N. A. N. A. Patented [6]
PMID25522065-Compound-29 DMBNAK9 N. A. N. A. Patented [6]
PMID25522065-Compound-34 DMZDIRQ N. A. N. A. Patented [6]
PMID25522065-Compound-39 DM5YMQH N. A. N. A. Patented [6]
PMID25522065-Compound-40 DMCIQ01 N. A. N. A. Patented [6]
PMID25522065-Compound-11 DM410Z6 N. A. N. A. Patented [6]
PMID25522065-Compound-50 DMBWA0V N. A. N. A. Patented [6]
PMID25522065-Compound-12 DMVKO9C N. A. N. A. Patented [6]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Voltage-gated potassium channel Kv11.1 (KCNH2)
Drug Name Drug ID Indication ICD 11 Highest Status REF
VESNARINONE DMBKX3C Cardiac failure BD10-BD13 Approved [7]
M100907 DM7ZFBA Sleep-wake disorder 7A00-7B2Z Phase 3 [8]
HP-184 DMNOMV2 Multiple sclerosis 8A40 Phase 2 [9]
NITD609 DMQHBSX Malaria 1F40-1F45 Phase 2 [10]
ABT-229 DMN3S1B Pain MG30-MG3Z Phase 2 [11]
ISOQUINE DMR17YI Malaria 1F40-1F45 Phase 1 [12]
Pyrido[3,2-e][1,2,4]triazolo[4,3-a]pyrazine derivative 1 DMC8935 N. A. N. A. Patented [13]
Isoindoline derivative 5 DMIUTQW N. A. N. A. Patented [14]
Isoindoline derivative 3 DM2MYL9 N. A. N. A. Patented [14]
Isoindoline derivative 4 DMP1NKI N. A. N. A. Patented [14]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Melanin-concentrating hormone receptor 1 (MCHR1) TTX4RTB MCHR1_HUMAN Antagonist [2]
Voltage-gated potassium channel Kv11.1 (KCNH2) TTQ6VDM KCNH2_HUMAN Inhibitor [3]

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4033).
2 The discovery and optimization of pyrimidinone-containing MCH R1 antagonists. Bioorg Med Chem Lett. 2006 Sep 15;16(18):4723-7.
3 Novel approach for chemotype hopping based on annotated databases of chemically feasible fragments and a prospective case study: new melanin concen... J Med Chem. 2009 Apr 9;52(7):2076-89.
4 2011 Pipeline of Bristol-Myers Squibb.
5 Phase I clinical trial of AZD1979 for treating obesity. AstraZeneca plc
6 Novel MCH1 receptor antagonists: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):193-207.
7 Prediction of hERG potassium channel affinity by traditional and hologram qSAR methods. Bioorg Med Chem Lett. 2003 Aug 18;13(16):2773-5.
8 Non-basic ligands for aminergic GPCRs: the discovery and development diaryl sulfones as selective, orally bioavailable 5-HT2A receptor antagonists ... Bioorg Med Chem Lett. 2010 Jun 15;20(12):3708-12.
9 Emerging drugs for spinal cord injury. Expert Opin Emerg Drugs. 2008 Mar;13(1):63-80.
10 Spiroindolones, a potent compound class for the treatment of malaria. Science. 2010 Sep 3;329(5996):1175-80.
11 9-Dihydroerythromycin ethers as motilin agonists--developing structure-activity relationships for potency and safety. Bioorg Med Chem. 2010 Nov 1;18(21):7651-8.
12 Candidate selection and preclinical evaluation of N-tert-butyl isoquine (GSK369796), an affordable and effective 4-aminoquinoline antimalarial for ... J Med Chem. 2009 Mar 12;52(5):1408-15.
13 Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2016 Aug;26(8):933-46.
14 The sigma-2 (-2) receptor: a review of recent patent applications: 2013-2018.Expert Opin Ther Pat. 2018 Sep;28(9):655-663.